Artificial Intelligence to Usher in New Era of Drug Safety Automation

☞ | View the text of this post. Exclusively available to ASQ Members.

Genpact is investing in leading digital technologies that are transforming industries. Genpacts Pharmacovigilance Artificial Intelligence (PVAI) will be the life sciences industry’s first fully-integrated, end-to-end adverse event (AE) processing solution, leveraging intelligent automation to not only dramatically reduce the effort of processing adverse events, but also to enable an AI-driven level of real-time predictive analytics and actionable insight not previously possible.

As life sciences companies face escalating AE volumes for their products and increasing pressure to

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *